# GLOW peptide references: the cited constituent literature and FDA sources

> GLOW peptide references — the full cited literature behind this digest: the GHK-Cu, BPC-157 and TB-500 constituent studies, the 2025-2026 reviews, and the FDA 503A compounding sources, with DOIs and URLs.

The constituent literature, the recent reviews, and the FDA compounding sources behind every quantitative claim on this site — with DOIs, PMIDs and URLs.

## About these GLOW peptide references

These GLOW peptide references are the complete cited basis for this digest. The constituent studies (1-7) ground every quantitative claim about GHK-Cu, BPC-157 and TB-500; the 2025-2026 reviews (10-11) supply the current investigational framing; and the FDA sources (12-15) underpin the regulatory and compounding-access record. There is no entry for a trial of the GLOW blend itself, because none exists — every number on this site is a constituent-level or regulatory fact, traced to its source below.

## References

[1] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[2] Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. https://pubmed.ncbi.nlm.nih.gov/18644225/
[3] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21:976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[4] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[5] Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
[6] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[7] Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology. 2016;28(4):438-443. https://pmc.ncbi.nlm.nih.gov/articles/PMC4969472/
[9] Research-label formulation convention for the GLOW blend (10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial), described as a supplier labeling convention rather than a clinically validated dose. Compositional note compiled from the constituent research record; the blend is not a single regulated product and has no controlled trial.
[10] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[11] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[12] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for BPC-157; 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; and 'GHK-Cu (for injectable routes of administration)', effective with the September 29, 2023 nominated-substances update.) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[13] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B framework and bulks-list nomination process.) https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[14] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157, KPV, TB-500 and MOTs-C as bulk drug substances being considered for inclusion on the 503A bulks list — a scheduled discussion, not a decision; GHK-Cu is not on this agenda.) https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
[15] U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved but Are FDA-Regulated. (Basis for the cosmetic-versus-drug distinction underlying GHK-Cu's dual status: topical 'Copper Tripeptide-1' is regulated under cosmetics rules and not subject to FDA pre-market drug approval, separate from the injectable-drug compounding question.) https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated

---

An illustrated night-lithograph of the GLOW peptide literature — GHK-Cu, BPC-157 and TB-500 set down as engraved study plates and weighed against their sources, with no clinic behind the gaslight and nothing here to dispense.